Hemolens Diagnostics® Ranks Among Poland’s TOP10 Innovators in the EPO Patent Index 2024

Hemolens Diagnostics® has officially secured its spot among the top innovators in Poland, as revealed in the European Patent Office (EPO) Patent Index 2024. This prestigious ranking highlights the companies and institutions driving technological advancements, with Hemolens® placing 10th among innovative companies in Poland. This milestone underscores Hemolens’® commitment to advancing non-invasive cardiac diagnostics, a field poised to revolutionize healthcare globally.

Europe’s Innovation Powerhouse: The EPO Patent Index 2024

The EPO Patent Index 2024 showcases a record of over 174,600 patent applications filed across Europe, reaffirming the continent’s position as a global leader in innovation. Of the 692 patent applications from Poland alone—a 3.4% increase over 2023—Hemolens Diagnostics® stands proudly among the top private sector contributors, demonstrating the company’s dedication to transforming MedTech and cardiovascular healthcare.  Top Innovators in Poland

While universities and research institutions play a key role in shaping Poland’s innovative landscape, private companies like Hemolens® are leading the way in translating cutting-edge research into real-world solutions.

The top 10 applicants from Poland in 2024 are:

1. AGH University of Science and Technology – 35 applications
2. Warsaw University of Technology – 25 applications
3. Ryvu Therapeutics – 18 applications
4. Jagiellonian University – 14 applications
5. Polish Academy of Sciences – 12 applications
6. Łukasiewicz Research Network – ITE – 12 applications
7. Medical University of Gdańsk – 11 applications
8. Gdańsk University of Technology – 9 applications
9. Wrocław University of Science and Technology – 8 applications
10. Hemolens Diagnostics® – 7 applications

Hemolens® ranks 10th overall in Poland and 3rd in private sector companies, with 7 patent applications filed in 2024, placing the company in elite company alongside some of the most prominent academic institutions and biotech firms. This recognition is a testament to Hemolens’® strong position within the global innovation ecosystem.The Strategic Importance of Patents

At Hemolens®, innovation goes beyond concepts and ideas; it’s about protecting those ideas and transforming them into impactful solutions. Patents serve as both legal protection and strategic assets, ensuring that groundbreaking technologies are safeguarded and ready for market deployment. Hemolens’® patents are essential not only in securing the company’s position as a pioneer in MedTech but also in helping shape the future of cardiovascular healthcare worldwide.

Hemolens’ Contribution to Global Innovation

This achievement would not have been possible without the brilliant team driving innovation at Hemolens® and Innovation Guardians (Hemolens® IP Department) and JWP Patent & Trademark Attorneys, supporting Hemolens® in ensuring global protection for its innovations.
This collaboration strengthens company’s technological portfolio, reinforcing Hemolens® commitment to innovation and leadership in the MedTech industry.

About EPO

The European Patent Office (EPO) plays a vital role in protecting intellectual property, enabling companies like Hemolens® to secure their innovations and compete on the global stage. By providing a comprehensive and effective patent system across 45 countries, the EPO strengthens Europe’s leadership in technological advancement and fosters continued progress in key sectors like MedTech.

About Hemolens Diagnostics®

Hemolens Diagnostics® is dedicated to advancing non-invasive cardiac diagnostic technologies that aim to revolutionize the detection and management of cardiovascular diseases. Through our innovative solutions – Cardiolens® Platform, we are committed to improving patient outcomes while optimizing healthcare resources globally.

#Innovation #MedTech #EPO #PatentIndex2024 #Hemolens #GlobalInnovation #CardiacCare